Arthroplasty for tenosynovial giant cell tumors.

Autor: Verspoor FG; a Department of Orthopedics , Radboud University Medical Center , Nijmegen , the Netherlands., Hannink G; a Department of Orthopedics , Radboud University Medical Center , Nijmegen , the Netherlands., Scholte A; a Department of Orthopedics , Radboud University Medical Center , Nijmegen , the Netherlands., Van Der Geest IC; a Department of Orthopedics , Radboud University Medical Center , Nijmegen , the Netherlands., Schreuder HW; a Department of Orthopedics , Radboud University Medical Center , Nijmegen , the Netherlands.
Jazyk: angličtina
Zdroj: Acta orthopaedica [Acta Orthop] 2016 Oct; Vol. 87 (5), pp. 497-503. Date of Electronic Publication: 2016 Jun 30.
DOI: 10.1080/17453674.2016.1205168
Abstrakt: Background and purpose - Tenosynovial giant cell tumors (t-GCTs) can behave aggressively locally and affect joint function and quality of life. The role of arthroplasty in the treatment of t-GCT is uncertain. We report the results of arthroplasty in t-GCT patients. Patients and methods - t-GCT patients (12 knee, 5 hip) received an arthroplasty between 1985 and 2015. Indication for arthroplasty, recurrences, complications, quality of life, and functional scores were evaluated after a mean follow-up time of 5.5 (0.2-15) years. Results - 2 patients had recurrent disease. 2 other patients had implant loosening. Functional scores showed poor results in almost half of the knee patients. 4 of the hip patients scored excellent and 1 scored fair. Quality of life was reduced in 1 or more subscales for 2 hip patients and for 5 knee patients. Interpretation - In t-GCT patients with extensive disease or osteoarthritis, joint arthroplasty is an additional treatment option. However, recurrences, implant loosening, and other complications do occur, even after several years.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje